Tag: Serum Institute

Garnering a massive chunk of revenue owing to Covid-19 push, India’s indigenous vaccines now proudly dominate the biopharma segment. Here we analyze the fresh impetus and the outlook

A formal announcement of this vaccine will be made by the Minister of State (IC) for Science and Technology, Dr Jitendra Singh in New Delhi today

With the government panel's backing, Serum Institute of India's Quadrivalent Human Papillomavirus vaccine (qHPV) is expected to hit the markets soon

The R&D centre will lead the development of new vaccines, technologies, products, and innovations in immunization practices

BBL will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets. SILS to receive ~15% stake in BBL at a post-money valuation of ~$4.9 billion......................

Serum Institute of India (SII) acquires 50% stake of SCHOTT Kaisha to become SCHOTT’s joint venture partner and secure pharma packaging supply..........................

Technology transfer process has already started; cultivation process has begun following the approval by the Drug Controller General of India (DCGI).........................

The prime minister, Narendra Modi interacted with vaccine manufacturers from across the country on April 20, 2021........................

A lot many vaccines are expected to be granted Emergency Use Authorization in other countries for expanding the basket of vaccines for domestic use and hasten the pace and coverage of vaccination....................

After adequate examination, Central Drugs Standard Control Organisation decided to accept the recommendations of the Expert Committee, and accordingly, vaccines of Serum and Bharat Biotech are being approved for restricted use in an emergency situation